Kidney Outcomes with Tirzepatide in Type 2 Diabetes
Episode 17, Jul 22, 2022, 07:58 PM
Dr Hiddo Heerspink joins Primary Viewpoints to discuss findings he recently presented at the American Diabetes Association 2022 Scientific Sessions from a pre-specified analysis of the SURPASS-4 clinical trial of tirzepatide that looked for the first time at the effects of the novel GLP-1 receptor agonist on kidney function in patients with type 2 diabetes.
Hiddo Heerspink, PhD, PharmD, is professor of clinical trials and personalized medicine and a clinical pharmacologist/trialist in the department of clinical pharmacy and pharmacology at the University Medical Center Groningen in Groningen, Netherlands; he is also Codirector of the Better Treatments Program at the George Institute for Global Health in Newtown, Australia.
Hiddo Heerspink, PhD, PharmD, is professor of clinical trials and personalized medicine and a clinical pharmacologist/trialist in the department of clinical pharmacy and pharmacology at the University Medical Center Groningen in Groningen, Netherlands; he is also Codirector of the Better Treatments Program at the George Institute for Global Health in Newtown, Australia.